Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for diagnosing, evaluating or testing cancer and foreseeing cancer severity

A technology for severity and cancer, applied in the field of determination of human neutrophil gelatinase-associated lipocalin content in patient urine, can solve the problem that cancer patients have no best results

Inactive Publication Date: 2009-10-28
CUSABIO TECH LLC
View PDF0 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] There is currently no best way to treat cancer patients. The most important way to improve the survival rate of cancer patients is early diagnosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] Example 1 Latex Enhanced Immunoturbidimetry Detects NGAL Content in Patient's Urine

[0015] Realize the technical scheme of this example: an immunoturbidimetric method for detecting human neutrophil gelatinase-associated lipocalin (NGAL), first cross-link with latex with anti-NGAL polyclonal antibody, and then use the cross-linked The latex solution reacts with the NGAL of the specimen to be tested, and the complex formed causes a change in turbidity; this change is characterized by light projection intensity or light scattering intensity; from the concentration of NGAL standard substance and the corresponding light scattering intensity or light projection intensity The standard curve finds the NGAL content of the sample to be tested; the polyclonal antibody titer of the NGAL used is at least 1:500, does not contain mixed antibodies, and has multiple antigenic determinants for recognizing NGAL; the sample to be tested is made 1:1 with a diluent 200-1:1000 dilution.

...

Embodiment 2

[0017] Embodiment 2 Determines patient's urine NGAL concentration with sandwich method ELISA

[0018] The specific steps are: coating NGAL antibody A; preparing a series of NGAL standard products; preparing patient urine; adding a series of standard products or patient urine with undetermined values ​​into the wells of a 96-microwell plate, and then making the labeled and binding sites different Bind to Antibody B coated on Antibody A on a 96-microwell plate, develop color with substrate solution for 20-30 minutes, then stop color development, and measure the NGAL in the above series of standards and the urine of the patient to be tested after 10 minutes. Absorbance; establish a standard curve of the concentration and absorbance of a series of standard substances and find out the concentration of NGAL in the urine of the patient whose value is to be determined from the curve.

Embodiment 3

[0019] Embodiment 3 Determines patient's urine NGAL concentration with competition method ELISA

[0020] The specific steps are: coating NGAL polyclonal antibody; preparing a series of NGAL standard products; preparing patient urine; mixing the series of standard products or patient urine with undetermined values ​​and labeled NGAL standard products; developing color with matrix solution for 20-30 Stop the color development after 10 minutes, and measure the absorbance of the above series of standard products and the NGAL reaction in the urine of the patient to be tested after 10 minutes; establish a standard curve of the concentration and absorbance of the series of standard products and find out the patient's urine with the undetermined value from the curve. The concentration of NGAL in the solution.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a method for diagnosing, evaluating or testing a cancer and foreseeing the severity of the cancer. The testing method comprises the following steps: an antibody of anti-human tropic neutrophil gelatinase-associated lipocalin (NGAL) is reacted with the human NGAL of a specimen to be tested to form a compound which causes turbidity change; light protection intensity or light scattering intensity is used for presenting the change; the human NGAL content of the specimen to be tested is tested through a standard curve of the concentration of human NGAL standard to relevant light protection intensity or light scattering intensity; and finally the cancer severity is measured based on the tested NGAL content. The method has the advantages of high flexibility, high recovery and good repetitiveness, determines a testing method with great convenience, good repetitiveness and strong suitability for the NGAL in urine or blood plasma of a cancer patient, and provides possibility for the clinical directive function of human NGAL and further research of the functions of the human NGAL.

Description

technical field [0001] The present invention relates to a method of diagnostically evaluating or measuring cancer and predicting the severity of said disease. Specifically, it relates to a method for determining the content of human neutrophil gelatinase-associated lipocalin (NGAL) in patient's urine. Background technique [0002] There is currently no best way to treat cancer patients, and the most important way to improve the survival rate of cancer patients is early diagnosis. Finding targets for early diagnosis of cancer provides indelible help in cancer prevention. With the development of gene analysis and proteomics, research on cancer-related molecules and molecular markers has also made great progress. For example, the prostate specific antigen (PSA) can be detected in the blood of prostate cancer patients, and can indicate the presence of prostate cancer, so that patients can quickly detect whether they have prostate cancer by detecting the level of PSA in the blo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/574G01N33/53G01N33/577G01N33/542G01N21/51G01N21/31G01N21/59
Inventor 华权高
Owner CUSABIO TECH LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com